Jay Lichter, Avalon BioVentures CEO
Avalon Ventures spins off a separate fund to handle life science companies — armed with $135M
Avalon Ventures has been a major player in the investing games both in tech and in the biotech world, but now a new fund …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
